Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in Lancet Gastroenterol Hepatol Retrieve available abstracts of 129 articles: HTML format

Single Articles

November 2026
1. HONAP S, Dignass A, Jairath V, Danese S, et al
   Defining molecular remission in inflammatory bowel disease: lessons from oncology.
   Lancet Gastroenterol Hepatol. 2026;11:944-946.
   PubMed    
   
   
   October 2026
2. TURNER D, Ricciuto A, Yuval Bar-Asher S, Vuyyuru SK, et al
   Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD.
   Lancet Gastroenterol Hepatol. 2026 Oct 19:S2468-1253(26)00292.
   PubMed     Abstract available
   
   
   September 2026
3. NOOR NM, Sharip MT, Zheng H, Widmer B, et al
   Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial.
   Lancet Gastroenterol Hepatol. 2026 Sep 10:S2468-1253(26)00192.
   PubMed     Abstract available
   
   
   
4. SIEGMUND B
   A decade in inflammatory bowel disease: progress, plateaus, and perspectives.
   Lancet Gastroenterol Hepatol. 2026;11:735-736.
   PubMed    
   
   
   
5. GUNAWAN J, Bernstein CN, Kaplan GG, Acosta MB, et al
   Incidence of inflammatory bowel disease in Jakarta, Indonesia, 2021-24.
   Lancet Gastroenterol Hepatol. 2026 Sep 1:S2468-1253(26)00239.
   PubMed    
   
   
   August 2026
6. OKABAYASHI S, Hracs L, Windsor JW, Gorospe J, et al
   The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence.
   Lancet Gastroenterol Hepatol. 2026 Aug 12:S2468-1253(26)00162.
   PubMed     Abstract available
   
   
   July 2026
7. REINISCH W, Stepek D, Kempinski R, Danese S, et al
   Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
   Lancet Gastroenterol Hepatol. 2026 Jul 16:S2468-1253(26)00120.
   PubMed     Abstract available
   
   
   
8. JAIRATH V, Kierkus J, Duvall GA, Danese S, et al
   Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
   Lancet Gastroenterol Hepatol. 2026 Jul 16:S2468-1253(26)00119.
   PubMed     Abstract available
   
   
   
9. OLDENBURG L, Haanappel AEG, D'Haens GR, Bemelman WA, et al
   Upfront medical or surgical treatment in Crohn's disease - Authors' reply.
   Lancet Gastroenterol Hepatol. 2026;11:552-553.
   PubMed    
   
   
   
10. NOOR NM, Fleshner PR, Melmed GY, Siegel CA, et al
    Upfront medical or surgical treatment in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:551-552.
    PubMed    
    
    
    
11. BANCIL AS, Giles EM, Fitzpatrick J
    Cyclic exclusive enteral nutrition in paediatric Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:550.
    PubMed    
    
    
    
12. PIGNEUR B, Ruemmele FM
    Cyclic exclusive enteral nutrition in paediatric Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:550-551.
    PubMed    
    
    
    June 2026
13. ZHANG Q, Shakweh E, Sharip MT, Zare B, et al
    HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association study.
    Lancet Gastroenterol Hepatol. 2026 Jun 15:S2468-1253(26)00113.
    PubMed     Abstract available
    
    
    
14. VISSER E, Buskens CJ
    Appendicectomy: a disease-modifying treatment for ulcerative colitis? - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:447.
    PubMed    
    
    
    
15. ARDABILI AR, Mujagic Z, Agrawal M, Jess T, et al
    Appendicectomy: a disease-modifying treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2026;11:446.
    PubMed    
    
    
    May 2026
16. MA C, Albashir S, Allocca M, de Buck van Overstraeten A, et al
    Intestinal ultrasound to detect postoperative recurrence in patients with Crohn's disease: an international, multidisciplinary, RAND/UCLA appropriateness method study.
    Lancet Gastroenterol Hepatol. 2026 May 20:S2468-1253(26)00082.
    PubMed     Abstract available
    
    
    
17. SOLITANO V, Jairath V, Magro F, Armuzzi A, et al
    Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?
    Lancet Gastroenterol Hepatol. 2026 May 14:S2468-1253(26)00085.
    PubMed     Abstract available
    
    
    March 2026
18. D'HAENS GR, Oldenburg L, Hulshoff MS
    Vedolizumab treatment outcomes in early versus late Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:184-185.
    PubMed    
    
    
    
19. CHEN R, Croitoru K, Lee SH
    Vedolizumab treatment outcomes in early versus late Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:183-184.
    PubMed    
    
    
    
20. NOOR NM, Hart AL, Lee JC, Parkes M, et al
    Vedolizumab treatment outcomes in early versus late Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026;11:182-183.
    PubMed    
    
    
    February 2026
21. OLDENBURG L, Haanappel AEG, Ali M, Bosman C, et al
    Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2026 Feb 19:S2468-1253(25)00374.
    PubMed     Abstract available
    
    
    
22. HONAP S, Jairath V, Magro F, Danese S, et al
    Clinical remission in ulcerative colitis: restoring precision in trial terminology.
    Lancet Gastroenterol Hepatol. 2026;11:96-97.
    PubMed    
    
    
    January 2026
23. ARMET AM, Wine E
    Cyclic exclusive enteral nutrition: a novel approach to maintaining remission in paediatric Crohn's disease.
    Lancet Gastroenterol Hepatol. 2026 Jan 19:S2468-1253(25)00325.
    PubMed    
    
    
    
24. PIGNEUR B, Martinez-Vinson C, Bourmaud A, Dabadie A, et al
    Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2026 Jan 19:S2468-1253(25)00262.
    PubMed     Abstract available
    
    
    
25. LONG M, Allegretti JR, Danese S, Germinaro M, et al
    Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2026 Jan 13:S2468-1253(25)00322.
    PubMed     Abstract available
    
    
    
26. CONLEY S, Kamp KJ, Kane SV
    Menopause and inflammatory bowel disease: more questions than answers.
    Lancet Gastroenterol Hepatol. 2026 Jan 13:S2468-1253(25)00368.
    PubMed    
    
    
    
27. COHEN NA, Bettenworth D, Sror N, Khedraki R, et al
    Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study.
    Lancet Gastroenterol Hepatol. 2026 Jan 8:S2468-1253(25)00347.
    PubMed     Abstract available
    
    
    
28. TODESCATTO AD, Kotze PG
    Appendicectomy: a disease-modifying treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2026 Jan 6:S2468-1253(25)00303.
    PubMed    
    
    
    
29. VISSER E, Reijntjes MA, Heuthorst L, Stellingwerf ME, et al
    Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study.
    Lancet Gastroenterol Hepatol. 2026 Jan 6:S2468-1253(25)00291.
    PubMed     Abstract available
    
    
    November 2025
30. SHEBAB M, Al-Hindawi A, Goodwin SW, Yuan Y, et al
    Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2025 Nov 25:S2468-1253(25)00346.
    PubMed    
    
    
    
31. VUIJK SA, Boute EH, de Ridder L
    Expanding the therapeutic arsenal for paediatric ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00234.
    PubMed    
    
    
    
32. KAPLAN JL, Bousvaros A, Turner D, Dubinsky M, et al
    Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.
    Lancet Gastroenterol Hepatol. 2025 Nov 18:S2468-1253(25)00196.
    PubMed     Abstract available
    
    
    
33. DE BOER NK, Gearry RB, Bernstein CN, Banerjee R, et al
    The essential medicines list for inflammatory bowel disease: time to raise the standards of global care.
    Lancet Gastroenterol Hepatol. 2025 Nov 17:S2468-1253(25)00299.
    PubMed    
    
    
    
34. JAIRATH V, Danese S, D'Haens GR, Feagan BG, et al
    Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
    Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00296.
    PubMed     Abstract available
    
    
    
35. ATREYA R, Neurath MF
    Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Nov 13:S2468-1253(25)00330.
    PubMed    
    
    
    
36. LI YIM AYF, Levin E, de Jonge WJ, Henneman P, et al
    Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:973-974.
    PubMed    
    
    
    
37. LI H, Zeng J, Zhang L, Guo Q, et al
    Peripheral blood DNA methylation signatures to predict treatment response in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:972-973.
    PubMed    
    
    
    October 2025
38. EGGERMONT E, Gecse K, Krugliak Cleveland N, Petersen F, et al
    Ulcerative colitis: moving beyond the mucosal dogma.
    Lancet Gastroenterol Hepatol. 2025 Oct 28:S2468-1253(25)00263.
    PubMed     Abstract available
    
    
    
39. HOIVIK ML
    Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00258.
    PubMed    
    
    
    
40. D'HAENS GR, Lowenberg M, Baert F, Bossuyt P, et al
    Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00233.
    PubMed     Abstract available
    
    
    September 2025
41. WU K, Zheng C, Cao Q, Ding Y, et al
    Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
    Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198.
    PubMed     Abstract available
    
    
    
42. VISSER E, Buskens CJ
    Appendicectomy for ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:789-790.
    PubMed    
    
    
    
43. SCARPA M, Castagliuolo I, Kotsafti A, Angriman I, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788.
    PubMed    
    
    
    
44. BRONZE S, Agrawal M, Rodriguez-Lago I, Colombel JF, et al
    Appendicectomy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:788-789.
    PubMed    
    
    
    July 2025
45. DANESE S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, et al
    Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
    Lancet Gastroenterol Hepatol. 2025 Jul 21:S2468-1253(25)00129.
    PubMed     Abstract available
    
    
    
46. YOGAKANTHI S, Raine T
    Progress in validation of treatment-response biomarkers in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00138.
    PubMed    
    
    
    
47. JOUSTRA VW, Li Yim AYF, Henneman P, Hageman I, et al
    Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.
    Lancet Gastroenterol Hepatol. 2025 Jul 1:S2468-1253(25)00102.
    PubMed     Abstract available
    
    
    June 2025
48. BOUHNIK Y, Mary JY
    A new endoscopic paradigm: evaluating the EASE-CD score for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00127.
    PubMed    
    
    
    
49. MA C, Khanna R, Maguire BR, Zou G, et al
    Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.
    Lancet Gastroenterol Hepatol. 2025 Jun 9:S2468-1253(25)00093.
    PubMed     Abstract available
    
    
    
50. PANACCIONE R, Vermeire S, Danese S, Higgins PDR, et al
    Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study.
    Lancet Gastroenterol Hepatol. 2025;10:507-519.
    PubMed     Abstract available
    
    
    
51. NOOR NM, Parkes M, Raine T
    U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:492-493.
    PubMed    
    
    
    
52. NEURATH MF, Artis D, Becker C
    The intestinal barrier: a pivotal role in health, inflammation, and cancer.
    Lancet Gastroenterol Hepatol. 2025;10:573-592.
    PubMed     Abstract available
    
    
    May 2025
53. FEAGAN BG, Sands BE, Siegel CA, Dubinsky MC, et al
    Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00071.
    PubMed     Abstract available
    
    
    
54. LINDSAY J
    Tulisokibart shows promise for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025 May 30:S2468-1253(25)00103.
    PubMed    
    
    
    April 2025
55. HANNA LN, Munster LJ, Joshi S, Wendelien van der Bilt JD, et al
    Isolated perianal Crohn's disease: a systematic review and expert consensus proposing novel diagnostic criteria and management advice.
    Lancet Gastroenterol Hepatol. 2025 Apr 29:S2468-1253(25)00007.
    PubMed     Abstract available
    
    
    
56. UKASHI O, Ben-Horin S
    Appendicectomy: a novel treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00065.
    PubMed    
    
    
    
57. 
    Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.
    Lancet Gastroenterol Hepatol. 2025 Apr 11:S2468-1253(25)00026.
    PubMed     Abstract available
    
    
    
58. HONAP S, Agrinier N, Torres J, Croitoru K, et al
    Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design.
    Lancet Gastroenterol Hepatol. 2025 Apr 2:S2468-1253(24)00439.
    PubMed     Abstract available
    
    
    March 2025
59. SHENOY S, Jena A, Levinson C, Sharma V, et al
    Inflammatory bowel disease in south Asia: a scoping review.
    Lancet Gastroenterol Hepatol. 2025;10:259-274.
    PubMed     Abstract available
    
    
    
60. D'HAENS G
    Vedolizumab for prevention of recurrence of Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:194-195.
    PubMed    
    
    
    
61. HAMMOUDI N, Allez M
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193.
    PubMed    
    
    
    
62. NGUYEN A, Li Wai Suen CFD, Srinivasan A, Segal J, et al
    Vedolizumab for prevention of recurrence of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:193-194.
    PubMed    
    
    
    February 2025
63. TEMIDO MJ, Honap S, Jairath V, Vermeire S, et al
    Overcoming the challenges of overtreating and undertreating inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2025 Feb 4:S2468-1253(24)00355.
    PubMed     Abstract available
    
    
    
64. NOOR NM, Estevinho MM, Solitano V, Yuan Y, et al
    Applying the estimand framework to inflammatory bowel disease clinical trials.
    Lancet Gastroenterol Hepatol. 2025 Feb 3:S2468-1253(25)00004.
    PubMed    
    
    
    January 2025
65. SANDS BE, Panaccione R, D'Haens G, Schreiber S, et al
    Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386.
    PubMed     Abstract available
    
    
    
66. ATREYA R, Neurath MF
    No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00397.
    PubMed    
    
    
    
67. ATIA O, Shavit-Brunschwig Z, Lev-Tzion R, Stein R, et al
    Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.
    Lancet Gastroenterol Hepatol. 2025 Jan 6:S2468-1253(24)00319.
    PubMed     Abstract available
    
    
    
68. LI WAI SUEN CFD, Choy MC, Con D, De Cruz P, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:19.
    PubMed    
    
    
    
69. HOFFERT Y, Ferrante M, Verstockt B, Dreesen E, et al
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:18-19.
    PubMed    
    
    
    
70. COMAN D, Battat R
    Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2025;10:17-18.
    PubMed    
    
    
    
71. VAN DER DOES DE WILLEBOIS EML, Bemelman WA, Buskens CJ
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2025;10:16-17.
    PubMed    
    
    
    
72. COFFEY JC, Li Y, Walsh D, Connelly TM, et al
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15.
    PubMed    
    
    
    
73. KELM M, Flemming S
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:15-16.
    PubMed    
    
    
    
74. DUAN M, Li Y
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14-15.
    PubMed    
    
    
    
75. YADAV A
    Mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2025;10:14.
    PubMed    
    
    
    December 2024
76. AINSWORTH MA
    Does filgotinib work for Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00304.
    PubMed    
    
    
    
77. VERMEIRE S, Schreiber S, Rubin DT, D'Haens G, et al
    Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Dec 2:S2468-1253(24)00272.
    PubMed     Abstract available
    
    
    November 2024
78. D'HAENS G, Taxonera C, Lopez-Sanroman A, Nos P, et al
    Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00317.
    PubMed     Abstract available
    
    
    
79. MULLIGAN RJ, Lamb CA
    Vedolizumab prophylaxis against postoperative Crohn's disease recurrence.
    Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00352.
    PubMed    
    
    
    
80. ANDERSEN V, Pingel J, Sofelt HL, Hikmat Z, et al
    Sex and gender in inflammatory bowel disease outcomes and research.
    Lancet Gastroenterol Hepatol. 2024;9:1041-1051.
    PubMed     Abstract available
    
    
    
81. GOMOLLON F
    Do placebos harm patients in IBD trials?
    Lancet Gastroenterol Hepatol. 2024;9:970-972.
    PubMed    
    
    
    October 2024
82. LU C, Rosentreter R, Parker CE, Remillard J, et al
    International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement.
    Lancet Gastroenterol Hepatol. 2024 Oct 21:S2468-1253(24)00265.
    PubMed     Abstract available
    
    
    September 2024
83. GROS B, Blackwell J, Segal J, Black CJ, et al
    Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00233.
    PubMed     Abstract available
    
    
    
84. DIN S, Segal J, Blackwell J, Gros B, et al
    Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2024 Sep 19:S2468-1253(24)00264.
    PubMed     Abstract available
    
    
    
85. KEDIA S, Ahuja V
    Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00229.
    PubMed    
    
    
    
86. CHOY MC, Li Wai Suen CFD, Con D, Boyd K, et al
    Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Sep 2:S2468-1253(24)00200.
    PubMed     Abstract available
    
    
    July 2024
87. NOOR NM, Sebastian S, Parkes M, Raine T, et al
    The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 Jul 30:S2468-1253(24)00225.
    PubMed    
    
    
    
88. VAN DER DOES DE WILLEBOIS EML, Bellato V, Duijvestein M, van der Bilt JDW, et al
    Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00097.
    PubMed     Abstract available
    
    
    
89. CLICK B, Holubar SD
    Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?
    Lancet Gastroenterol Hepatol. 2024 Jul 15:S2468-1253(24)00186.
    PubMed    
    
    
    
90. CHEN R, Zhang S
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:592.
    PubMed    
    
    
    
91. NOOR NM, Lee JC, Bond S, Parkes M, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial - Authors' reply.
    Lancet Gastroenterol Hepatol. 2024;9:592-594.
    PubMed    
    
    
    
92. BORKAR V, Lunagariya Y, Chopra S, Sasikumar D, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591.
    PubMed    
    
    
    
93. SATSANGI J, Nowak J, Kalla R, Colombel JF, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:591-592.
    PubMed    
    
    
    
94. BOURGONJE AR, Visschedijk MC, Festen EAM, Weersma RK, et al
    Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial.
    Lancet Gastroenterol Hepatol. 2024;9:590-591.
    PubMed    
    
    
    June 2024
95. GUPTA A, Guisado D, Ricart E, Colombel JF, et al
    Haematopoietic stem-cell transplantation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024;9:499-500.
    PubMed    
    
    
    May 2024
96. IACUCCI M, Santacroce G, Zammarchi I, Maeda Y, et al
    Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2024 May 14:S2468-1253(24)00053.
    PubMed     Abstract available
    
    
    
97. BETHLEHEM L, Estevinho MM, Grinspan A, Magro F, et al
    Microbiota therapeutics for inflammatory bowel disease: the way forward.
    Lancet Gastroenterol Hepatol. 2024;9:476-486.
    PubMed     Abstract available
    
    
    
98. FUMERY M, Buisson A
    Has the time come for a systematic top-down approach in Crohn's disease?
    Lancet Gastroenterol Hepatol. 2024;9:394-395.
    PubMed    
    
    
    April 2024
99. PARKES GC, Hedin CRH
    PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00088.
    PubMed    
    
    
    
100. CHANCHLANI N, Lin S, Bewshea C, Hamilton B, et al
     Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
     Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044.
     PubMed     Abstract available
     
     
     March 2024
101. BALDERRAMO D, Quaresma AB, Olivera PA, Savio MC, et al
     Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
     Lancet Gastroenterol Hepatol. 2024;9:263-272.
     PubMed     Abstract available
     
     
     
102. RIVIERE P, Li Wai Suen C, Chaparro M, De Cruz P, et al
     Acute severe ulcerative colitis management: unanswered questions and latest insights.
     Lancet Gastroenterol Hepatol. 2024;9:251-262.
     PubMed     Abstract available
     
     
     February 2024
103. CHAPMAN TP, Ahmad T, Satsangi J
     Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
     Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
     PubMed    
     
     
     
104. NOOR NM, Lee JC, Bond S, Dowling F, et al
     A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
     Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
     PubMed     Abstract available
     
     
     
105. CICCOCIOPPO R, Gaspar L
     Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.
     Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(24)00004.
     PubMed    
     
     
     
106. LINDSAY JO, Hind D, Swaby L, Berntsson H, et al
     Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, ra
     Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(23)00460.
     PubMed     Abstract available
     
     
     January 2024
107. SEBASTIAN S, Siegmund B, Teferra F, McGovern DPB, et al
     Promoting equity in inflammatory bowel disease: a global approach to care.
     Lancet Gastroenterol Hepatol. 2024 Jan 11:S2468-1253(23)00368.
     PubMed    
     
     
     December 2023
108. FUMERY M, Buisson A
     Guselkumab in Crohn's disease: the IL-23 race continues.
     Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00356.
     PubMed    
     
     
     
109. DANESE S, Panaccione R, Feagan BG, Afzali A, et al
     Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
     Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318.
     PubMed     Abstract available
     
     
     October 2023
110. DIBLEY L, Duffy M
     Inflammatory bowel disease health care for LGTBQIA+ patients.
     Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
     PubMed    
     
     
     
111. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
     Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
     Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
     PubMed     Abstract available
     
     
     
112. QUAN J, Markovinovic A, Hracs L, Ma C, et al
     Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
     PubMed    
     
     
     September 2023
113. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
     Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
     Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
     PubMed     Abstract available
     
     
     
114. ATREYA R, Neurath MF
     Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
     PubMed    
     
     
     August 2023
115. SENIOR K
     Surgery in Crohn's disease: patients need MDT-led holistic care.
     Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
     PubMed    
     
     
     
116. SHIN A
     Psychological therapies in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
     PubMed    
     
     
     
117. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
     Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
     Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
     PubMed     Abstract available
     
     
     July 2023
118. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
     Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
     Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
     PubMed     Abstract available
     
     
     May 2023
119. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
     Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
     PubMed    
     
     
     
120. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
     The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
     Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
     PubMed    
     
     
     
121. JENA A, Sharma V, Sebastian S
     Reducing disparities in training in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
     PubMed    
     
     
     
122. BRIERLEY R
     18th Congress of the European Crohn's and Colitis Organisation.
     Lancet Gastroenterol Hepatol. 2023;8:404.
     PubMed    
     
     
     
123. LOUIS E
     Treatment de-escalation in Crohn's disease - Author's reply.
     Lancet Gastroenterol Hepatol. 2023;8:401-402.
     PubMed    
     
     
     
124. MCSHANE C, Kevans D
     Treatment de-escalation in Crohn's disease.
     Lancet Gastroenterol Hepatol. 2023;8:401.
     PubMed    
     
     
     
125. THE LANCET GASTROENTEROLOGY HE
     The economic burden of inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2023;8:391.
     PubMed    
     
     
     April 2023
126. SINGH S, Boland BS, Jess T, Moore AA, et al
     Management of inflammatory bowel diseases in older adults.
     Lancet Gastroenterol Hepatol. 2023;8:368-382.
     PubMed     Abstract available
     
     
     March 2023
127. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
     Inflammation and malnutrition in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
     PubMed     Abstract available
     
     
     
128. BANERJEE R, Raghunathan N, Pal P
     Managing inflammatory bowel disease: what to do when the best is unaffordable?
     Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
     PubMed    
     
     
     
129. BURISCH J, Zhao M, Odes S, De Cruz P, et al
     The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
     Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum